Cargando…

Newly developed anti-angiogenic therapy in non-small cell lung cancer

Angiogenesis and its role in the growth and development of non-small cell lung cancer (NSCLC) metastases has become an increasing clinical problem. Vascular endothelial growth factor (VEGF) plays a key role in advanced NSCLC. To some extent, anti-angiogenic therapies acquired some efficacy in combin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qu, Jingjing, Zhang, Yongchang, Chen, Xue, Yang, Haiyan, Zhou, Chunhua, Yang, Nong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5839380/ https://www.ncbi.nlm.nih.gov/pubmed/29515799 http://dx.doi.org/10.18632/oncotarget.23755

Ejemplares similares

The clinicopathologic of pulmonary adenocarcinoma transformation to small cell lung cancer
por: Yang, Haiyan, et al.
Publicado: (2019)

A Large Real-World Study on the Effectiveness of the Combined Inhibition of EGFR and MET in EGFR-Mutant Non-Small-Cell Lung Cancer After Development of EGFR-TKI Resistance
por: Liu, Li, et al.
Publicado: (2021)

Anti-Angiogenic Therapy in the Treatment of Non-Small Cell Lung Cancer
por: Tian, Wentao, et al.
Publicado: (2020)

Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker study
por: Zhang, Yongchang, et al.
Publicado: (2022)

Real‐world outcomes of various regimens of recombinant human endostatin combined with chemotherapy in non‐driver gene mutation advanced non‐small cell lung cancer
por: Wang, Zhongtai, et al.
Publicado: (2019)

Anti-Angiogenic Therapy in ALK Rearranged Non-Small Cell Lung Cancer (NSCLC)
por: Tan, Aaron C., et al.
Publicado: (2022)

The serum activity of thioredoxin reductases 1 (TrxR1) is correlated with the poor prognosis in EGFR wild-type and ALK negative non-small cell lung cancer
por: Chen, Gong, et al.
Publicado: (2017)

Anti-angiogenic agents in the treatment of non-small cell lung cancer
por: Szyszka-Barth, Katarzyna, et al.
Publicado: (2014)

Vascular phenotype in angiogenic and non-angiogenic lung non-small cell carcinomas
por: Passalidou, E, et al.
Publicado: (2002)

PIM1 inhibitor synergizes the anti-tumor effect of osimertinib via STAT3 dephosphorylation in EGFR-mutant non-small cell lung cancer
por: Sun, Ziyi, et al.
Publicado: (2020)

Genomic alterations associated with pseudoprogression and hyperprogressive disease during anti-PD1 treatment for advanced non-small-cell lung cancer
por: Zhou, Rui, et al.
Publicado: (2023)

Combining radiotherapy with targeted therapies in non-small cell lung cancer: focus on anti-EGFR, anti-ALK and anti-angiogenic agents
por: Wrona, Anna, et al.
Publicado: (2021)

Beyond Conventional: The New Horizon of Anti-Angiogenic microRNAs in Non-Small Cell Lung Cancer Therapy
por: Tirpe, Alexandru, et al.
Publicado: (2020)

Crizotinib presented with promising efficacy but for concomitant mutation in next-generation sequencing-identified ROS1-rearranged non-small-cell lung cancer
por: Zeng, Liang, et al.
Publicado: (2018)

Blocking CD47 efficiently potentiated therapeutic effects of anti-angiogenic therapy in non-small cell lung cancer
por: Zhang, Xuyao, et al.
Publicado: (2019)

Dramatic Response to Teriprilumab and Anlotinib Combination Therapy in a patient with EGFR-Mutant Lung Adenocarcinoma Who Experienced Small-Cell Transformation−Mediated Erlotinib Resistance After Failure of Chemotherapy
por: Zhou, Yuling, et al.
Publicado: (2020)

Anti-Angiogenic Drugs Inhibit Interstitial Lung Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer
por: Wang, Yanning, et al.
Publicado: (2022)

Effects of combining immune checkpoint inhibitors and anti-angiogenic agents on bone metastasis in non-small cell lung cancer patients
por: Xie, Xiaohong, et al.
Publicado: (2023)

Angiogenic signaling pathways and anti-angiogenic therapy for cancer
por: Liu, Zhen-Ling, et al.
Publicado: (2023)

Case Report: Transformation From Non-Small Cell Lung Cancer to Small Cell Lung Cancer During Anti-PD-1 Therapy: A Report of Two Cases
por: Shen, Qian, et al.
Publicado: (2021)

Prospect of immunotherapy combined with anti-angiogenic agents in patients with advanced non-small cell lung cancer
por: Liang, Hongge, et al.
Publicado: (2019)

Nephrotoxicity of Anti-Angiogenic Therapies
por: Van Wynsberghe, Margaux, et al.
Publicado: (2021)

The efficacy and safety of albumin-bound paclitaxel plus carboplatin as neoadjuvant therapy for potentially resectable lung squamous cell carcinoma: a real-world retrospective cohort study
por: Jiang, Wenjuan, et al.
Publicado: (2022)

Mechanisms of Tumor Development and Anti-angiogenic Therapy in Glioblastoma Multiforme
por: Onishi, Manabu, et al.
Publicado: (2013)

Recent Advancements of Monotherapy, Combination, and Sequential Treatment of EGFR/ALK-TKIs and ICIs in Non–Small Cell Lung Cancer
por: Liao, Dehua, et al.
Publicado: (2022)

The role of long non-coding RNAs in angiogenesis and anti-angiogenic therapy resistance in cancer
por: Liu, Junxia, et al.
Publicado: (2022)

Exploring immune checkpoint inhibition in combination with anti-angiogenic therapy for patients with EGFR- or ALK-positive advanced non-small cell lung cancer
por: De Giglio, Andrea, et al.
Publicado: (2022)

The promise of anti-angiogenic cancer therapy
por: Oehler, M K, et al.
Publicado: (2000)

Biomarkers for Anti-Angiogenic Therapy in Cancer
por: Wehland, Markus, et al.
Publicado: (2013)

Anti-angiogenic therapies in brain metastases
por: Berghoff, Anna S., et al.
Publicado: (2018)

Anti-angiogenic therapy for ovarian cancer
por: García García, Yolanda, et al.
Publicado: (2020)

Anti-angiogenic therapies in the management of glioblastoma
por: Schulte, Jessica D., et al.
Publicado: (2021)

Efficacy and Safety of Apatinib Plus Vinorelbine in Patients With Wild-Type Advanced Non–Small Cell Lung Cancer After Second-Line Treatment Failure: A Nonrandomized Clinical Trial
por: Zhang, Xiangyu, et al.
Publicado: (2020)

Combination of Immune Checkpoint Inhibitors and Anti-Angiogenic Agents in Brain Metastases From Non-Small Cell Lung Cancer
por: Fang, Likui, et al.
Publicado: (2021)

Immune Checkpoint and Anti-Angiogenic Antibodies for the Treatment of Non-Small Cell Lung Cancer in the European Union and United States
por: Ferreira, Marion, et al.
Publicado: (2021)

PD-1 inhibitor versus bevacizumab in combination with platinum-based chemotherapy for first-line treatment of advanced lung adenocarcinoma: A retrospective-real world study
por: Huang, Zhe, et al.
Publicado: (2022)

Prognostic and Predictive Role of Angiogenic Markers in Non- Small Cell Lung Cancer
por: Keskin, Serkan, et al.
Publicado: (2019)

Prognosis and Concurrent Genomic Alterations in Patients With Advanced NSCLC Harboring MET Amplification or MET Exon 14 Skipping Mutation Treated With MET Inhibitor: A Retrospective Study
por: Liu, Li, et al.
Publicado: (2021)

Novel risk scoring system for immune checkpoint inhibitors treatment in non-small cell lung cancer
por: Li, Chuling, et al.
Publicado: (2021)

Anti‐Metastatic and Anti‐Angiogenic Activities of Core–Shell SiO(2)@LDH Loaded with Etoposide in Non‐Small Cell Lung Cancer
por: Zhu, Yanjing, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_gm0gvva1cnjhbb1v7bf6h19sni